Cancer Research and Treatment

Volume 37(1); February 2005

Review Article

Biology of SNU Cell Lines: Ja-Lok Ku, Jae-Gahb Park; Cancer Res Treat. 2005;37(1):1-19. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.1

SNU (Seoul National University) cell lines have been established from Korean cancer patients since 1982. Of these 109 cell lines have been characterized and reported, i.e., 17 colorectal carcinoma, 12 hepatocellular carcinoma, 11 gastric carcinoma, 12 uterine cervical carcinoma, 17 B-lymphoblastoid cell lines derived from cancer patients, 5 ovarian carcinoma, 3 malignant mixed Mllerian tumor, 6 laryngeal squamous cell carcinoma, 7 renal cell carcinoma, 9 brain tumor, 6 biliary tract, and 4 pancreatic carcinoma cell lines. These SNU cell lines have been distributed to biomedical researchers domestic and worldwide through the KCLB (Korean Cell Line Bank), and have proven to be of value in various scientific research fields. The characteristics of these cell lines have been reported in over 180 international journals by our laboratory and by many other researchers from 1987. In this paper, the cellular and molecular characteristics of SNU human cancer cell lines are summarized according to their genetic and epigenetic alterations and functional analysis.

Citations

Citations to this article as recorded by

HPV, HBV, and HIV-1 Viral Integration Site Mapping: A Streamlined Workflow from NGS to Genomic Insights of Carcinogenesis
Jane Shen-Gunther, Acarizia Easley
Viruses.2024; 16(6): 975. CrossRef
Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy
Ozen Leylek, Megan E. Honeywell, Michael J. Lee, Michael T. Hemann, Gulnihal Ozcan
Gastric Cancer.2024; 27(6): 1201. CrossRef
Newcastle disease virus harboring the PTEN gene inhibits pancreatic cancer growth by inhibiting PI3K/AKT/mTOR signaling and activating apoptosis
Seonhee Kim, Bo-Kyoung Jung, Jinju Kim, Joo Hee Jeon, Sung Hoon Jang, Minsoo Kim, Cuk-Seong Kim, Hyun Jang
Molecular Therapy: Oncology.2024; 32(4): 200898. CrossRef
Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases
Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K Park, Audrey Jung, Jianming Lu, Sang-In Kim, Saul Priceman, Yuman Fong, Yanghee Woo
Journal for ImmunoTherapy of Cancer.2023; 11(4): e006280. CrossRef
In Vitro Study on AI‐PRS Enabled Precision Cocktail Drugs Design for Treating Human Colorectal Carcinoma
Hsin‐Yu Yang, Venkanagouda S. Goudar, Yi‐Chi Hung, Chih‐Hsuan Ouyang, Masturah Bte Mohd Abdul Rashid, Liang‐Yi Juo, Jen‐Kuei Wu, Ya‐Wen Cheng, Po‐Li Wei, Huey‐En Tzeng, Jeng‐Kai Jiang, Edward Kai‐Hua Chow, Chih‐Yung Yang, Chih‐Ming Ho, Yun Yen, Fan‐Gang T
Advanced Therapeutics.2023;[Epub] CrossRef
Exosomal MicroRNA and Protein Profiles of Hepatitis B Virus-Related Hepatocellular Carcinoma Cells
Valentina K. Todorova, Stephanie D. Byrum, Samuel G. Mackintosh, Azemat Jamshidi-Parsian, Allen J. Gies, Charity L. Washam, Samir V. Jenkins, Timothy Spiva, Emily Bowman, Nathan S. Reyna, Robert J. Griffin, Issam Makhoul
International Journal of Molecular Sciences.2023; 24(17): 13098. CrossRef
Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases
Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K. Park, Jianming Lu, Sang-In Kim, Hannah Valencia, Yuman Fong, Yanghee Woo
Molecular Therapy - Oncolytics.2023; 31: 100734. CrossRef
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
Raghav Sundar, Kie-Kyon Huang, Vikrant Kumar, Kalpana Ramnarayanan, Deniz Demircioglu, Zhisheng Her, Xuewen Ong, Zul Fazreen Bin Adam Isa, Manjie Xing, Angie Lay-Keng Tan, David Wai Meng Tai, Su Pin Choo, Weiwei Zhai, Jia Qi Lim, Meghna Das Thakur, Lucian
Gut.2022; 71(7): 1277. CrossRef
Regulation of GTPase function by autophosphorylation
Christian W. Johnson, Hyuk-Soo Seo, Elizabeth M. Terrell, Moon-Hee Yang, Fenneke KleinJan, Teklab Gebregiworgis, Genevieve M.C. Gasmi-Seabrook, Ezekiel A. Geffken, Jimit Lakhani, Kijun Song, Puspalata Bashyal, Olesja Popow, Joao A. Paulo, Andrea Liu, Carl
Molecular Cell.2022; 82(5): 950. CrossRef
Corilagin exhibits differential anticancer effects through the modulation of STAT3/5 and MAPKs in human gastric cancer cells
Min Hee Yang, Seung Ho Baek, Sun Tae Hwang, Jae‐Young Um, Kwang Seok Ahn
Phytotherapy Research.2022; 36(6): 2449. CrossRef
Subcellular progression of mesenchymal transition identified by two discrete synchronous cell lines derived from the same glioblastoma
Sojin Kim, Soo-Ji Park, Tamrin Chowdhury, Jeong-Im Hong, Jinhee Ahn, Tae Yeong Jeong, Hyeon Jong Yu, Young-Kyoung Shin, Ja-Lok Ku, Jong Bae Park, Junho K. Hur, Hwajin Lee, Kyoungmi Kim, Chul‑Kee Park
Cellular and Molecular Life Sciences.2022;[Epub] CrossRef
Comparative Study of Autophagy in Oxaliplatin-Sensitive and Resistant SNU-C5 Colon Cancer Cells
Sun-Jin Boo, Mei Jing Piao, Kyoung Ah Kang, Ao Xuan Zhen, Pincha Devage Sameera Madushan Fernando, Herath Mudiyanselage Udari Lakmini Herath, Seung Joo Lee, Seung Eun Song, Jin Won Hyun
Biomolecules & Therapeutics.2022; 30(5): 447. CrossRef
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment
Stephanie Busche, Katharina John, Franziska Wandrer, Florian W. R. Vondran, Ulrich Lehmann, Heiner Wedemeyer, Frank Essmann, Klaus Schulze-Osthoff, Heike Bantel
Cell Death & Disease.2021;[Epub] CrossRef
The role of transforming growth factor β in upper gastrointestinal cancers: A systematic review
Linde M. Veen, Tim L.P. Skrabanja, Sarah Derks, Tanja D. de Gruijl, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven
Cancer Treatment Reviews.2021; 100: 102285. CrossRef
Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
Yanping Yang, Jaclyn E. McCloskey, Huan Yang, Janusz Puc, Yago Alcaina, Yogindra Vedvyas, Angel A. Gomez Gallegos, Elizabeth Ortiz-Sánchez, Elisa de Stanchina, Irene M. Min, Eric von Hofe, Moonsoo M. Jin
Cancer Immunology Research.2021; 9(10): 1158. CrossRef
Identification and Functional Characterization of Two Noncoding RNAs Transcribed from Putative Active Enhancers in Hepatocellular Carcinoma
Ye-Eun Lee, Jiyeon Lee, Yong Sun Lee, Jiyoung Joan Jang, Hyeonju Woo, Hae In Choi, Young Gyu Chai, Tae-Kyung Kim, TaeSoo Kim, Lark Kyun Kim, Sun Shim Choi
Molecules and Cells.2021; 44(9): 658. CrossRef
TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
Jin Won Kim, Ahrum Min, Seock-Ah Im, Hyemin Jang, Yu Jin Kim, Hee-Jun Kim, Kyung-Hun Lee, Tae-Yong Kim, Keun Wook Lee, Do-Youn Oh, Jee-Hyun Kim, Yung-Jue Bang
Cancers.2020; 12(2): 334. CrossRef
ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma
Heejin Kim, Joo Yeon Choi, Yoon Chan Rah, Jae-Cheul Ahn, Hyunchul Kim, Woo-Jin Jeong, Soon-Hyun Ahn
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2020; 129(4): 377. CrossRef
Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells
María A. Rodríguez-Hernández, Raquel Chapresto-Garzón, Miryam Cadenas, Elena Navarro-Villarán, María Negrete, Miguel A. Gómez-Bravo, Victor M. Victor, Francisco J. Padillo, Jordi Muntané
Cell Death & Disease.2020;[Epub] CrossRef
PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer
Kui-Jin Kim, Ji-Won Kim, Ji Hea Sung, Koung Jin Suh, Ji Yun Lee, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Hark Kyun Kim, Keun-Wook Lee
Scientific Reports.2020;[Epub] CrossRef
RhoA and Rac1 in Liver Cancer Cells: Induction of Overexpression Using Mechanical Stimulation
Sharda Yadav, Navid Kashaninejad, Nam-Trung Nguyen
Micromachines.2020; 11(8): 729. CrossRef
The glutathione peroxidase 8 (GPX8)/IL-6/STAT3 axis is essential in maintaining an aggressive breast cancer phenotype
Anees Khatib, Balakrishnan Solaimuthu, Michal Ben Yosef, Areej Abu Rmaileh, Mayur Tanna, Gidi Oren, Michal Schlesinger Frisch, Jonathan H. Axelrod, Michal Lichtenstein, Yoav D. Shaul
Proceedings of the National Academy of Sciences.2020; 117(35): 21420. CrossRef
CircRNA CircRIMS Acts as a MicroRNA Sponge to Promote Gastric Cancer Metastasis
Jun Lin, Yi Zhang, Xianchang Zeng, Chaorong Xue, Xu Lin
ACS Omega.2020; 5(36): 23237. CrossRef
Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells
Miso Lee, Kyung-Hun Lee, Ahrum Min, Jeongeun Kim, Seongyeong Kim, Hyemin Jang, Jee Min Lim, So Hyeon Kim, Dong-Hyeon Ha, Won Jae Jeong, Koung Jin Suh, Yae-Won Yang, Tae Yong Kim, Do-Youn Oh, Yung-Jue Bang, Seock-Ah Im
Cancer Research and Treatment.2019; 51(2): 451. CrossRef
Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
Ye‐Lim Park, Hwang‐Phill Kim, Young‐Won Cho, Dong‐Wook Min, Seul‐Ki Cheon, Yoo Joo Lim, Sang‐Hyun Song, Sung Jin Kim, Sae‐Won Han, Kyu Joo Park, Tae‐You Kim
International Journal of Cancer.2019; 144(2): 389. CrossRef
NFATC3–PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines
Jee-Eun Jang, Hwang-Phill Kim, Sae-Won Han, Hoon Jang, Si-Hyun Lee, Sang-Hyun Song, Duhee Bang, Tae-You Kim
Cancer Research and Treatment.2019; 51(1): 391. CrossRef
Augmented antitumor activity of 5‐fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells
Mamiko Imanishi, Yoshiyuki Yamamoto, Xiaoxuan Wang, Akinori Sugaya, Mitsuaki Hirose, Shinji Endo, Yukikazu Natori, Kenji Yamato, Ichinosuke Hyodo
Cancer Science.2019; 110(2): 639. CrossRef
Cytotoxicity of Human Hepatic Intrasinusoidal CD56bright Natural Killer Cells against Hepatocellular Carcinoma Cells
Shin Hwang, Jaeseok Han, Ji-Seok Baek, Eunyoung Tak, Gi-Won Song, Sung-Gyu Lee, Dong-Hwan Jung, Gil-Chun Park, Chul-Soo Ahn, Nayoung Kim
International Journal of Molecular Sciences.2019; 20(7): 1564. CrossRef
Cytolytic Activity of Effector T-lymphocytes Against Hepatocellular Carcinoma is Improved by Dendritic Cells Pulsed with Pooled Tumor Antigens
Thaweesak Chieochansin, Chutamas Thepmalee, Janya Grainok, Mutita Junking, Pa-thai Yenchitsomanus
Scientific Reports.2019;[Epub] CrossRef
Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer
S H Song, M S Jeon, J W Nam, J K Kang, Y J Lee, J Y Kang, H P Kim, S W Han, G H Kang, T Y Kim
Oncogene.2018; 37(8): 993. CrossRef
Galanin is an epigenetically silenced tumor suppressor gene in gastric cancer cells
Daseul Yoon, Kieun Bae, Min-Kyeong Lee, Jin Hee Kim, Kyong-Ah Yoon, Hiromu Suzuki
PLOS ONE.2018; 13(2): e0193275. CrossRef
Anti-tumour effects of beta-sitosterol are mediated by AMPK/PTEN/HSP90 axis in AGS human gastric adenocarcinoma cells and xenograft mouse models
Eun Ju Shin, Hyo-Kyoung Choi, Mi Jeong Sung, Jae Ho Park, Min-Yu Chung, Sangwon Chung, Jin-Taek Hwang
Biochemical Pharmacology.2018; 152: 60. CrossRef
Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells
Ahrum Min, Jung Eun Kim, Yu-Jin Kim, Jee Min Lim, Seongyeong Kim, Jin Won Kim, Kyung-Hun Lee, Tae-Yong Kim, Do-Youn Oh, Yung-Jue Bang, Seock-Ah Im
Cancer Letters.2018; 430: 123. CrossRef
Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
Seul‐Ki Cheon, Hwang‐Phill Kim, Ye‐Lim Park, Jee‐Eun Jang, Yoojoo Lim, Sang‐Hyun Song, Sae‐Won Han, Tae‐You Kim
Molecular Oncology.2018; 12(8): 1398. CrossRef
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Zhihao Wu, Hong-Fen Guo, Hong Xu, Nai-Kong V. Cheung
Molecular Cancer Therapeutics.2018; 17(10): 2164. CrossRef
Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis
Hyungjin Rhee, Hye-Young Kim, Ji-Hye Choi, Hyun Goo Woo, Jeong Eun Yoo, Ji Hae Nahm, Jin-Sub Choi, Young Nyun Park
Cancer Research.2018; 78(7): 1619. CrossRef
Modulation of transcription factor binding and epigenetic regulation of the MLH1 CpG island and shore by polymorphism rs1800734 in colorectal cancer
Andrea J. Savio, Bharati Bapat
Epigenetics.2017; 12(6): 441. CrossRef
Reduced Autophagy in 5-Fluorouracil Resistant Colon Cancer Cells
Cheng Wen Yao, Kyoung Ah Kang, Mei Jing Piao, Yea Seong Ryu, Pattage Madushan Dilhara Jayatissa Fernando, Min Chang Oh, Jeong Eon Park, Kristina Shilnikova, Soo-Young Na, Seung Uk Jeong, Sun-Jin Boo, Jin Won Hyun
Biomolecules & Therapeutics.2017; 25(3): 315. CrossRef
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Ahrum Min, Seock-Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, Debora Keunyoung Kim, Yaewon Yang, Hee-Jun Kim, Kyung-Hun Lee, Jin Won Kim, Tae-Yong Kim, Do-Youn Oh, Jeff Brown, Alan Lau, Mark J. O'Connor, Yung-Jue Bang
Molecular Cancer Therapeutics.2017; 16(4): 566. CrossRef
Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells
Paulina Grygielewicz, Barbara Dymek, Anna Bujak, Pawel Gunerka, Aleksandra Stanczak, Monika Lamparska-Przybysz, Maciej Wieczorek, Karolina Dzwonek, Daria Zdzalik
Gastric Cancer.2016; 19(1): 53. CrossRef
Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability
Jiyeon Yun, Sang-Hyun Song, Jee-Youn Kang, Jinah Park, Hwang-Phill Kim, Sae-Won Han, Tae-You Kim
Nucleic Acids Research.2016; 44(2): 558. CrossRef
Aberrant Epigenetic Modifications of LPHN2 Function as a Potential Cisplatin-Specific Biomarker for Human Gastrointestinal Cancer
Mi-Seong Jeon, Sang-Hyun Song, Jiyeon Yun, Jee-Youn Kang, Hwang-Phill Kim, Sae-Won Han, Tae-You Kim
Cancer Research and Treatment.2016; 48(2): 676. CrossRef
Carboxyl-Terminal Modulator Protein Positively Acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via Regulating Akt phosphorylation
Jae Won Chang, Seung-Nam Jung, Ju-Hee Kim, Geun-Ae Shim, Hee Sung Park, Lihua Liu, Jin Man Kim, Jongsun Park, Bon Seok Koo
Scientific Reports.2016;[Epub] CrossRef
C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties
Kai-Yu Ng, Stella Chai, Man Tong, Xin-Yuan Guan, Chi-Ho Lin, Yick-Pang Ching, Dan Xie, Alfred Sze-Lok Cheng, Stephanie Ma
Oncotarget.2016; 7(17): 24005. CrossRef
Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population
Jae Woo Jung, So-Mi Yoon, Subin Kim, Yun-Hui Jeon, Byung-Hak Yoon, Su-Geun Yang, Min Kyoung Kim, Senyon Choe, Mario Meng-Chiang Kuo
Oncotarget.2016; 7(45): 73754. CrossRef
Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage–Induced Senescence Program in Gastric Cancer
Paola Francica, Lluís Nisa, Daniel M. Aebersold, Rupert Langer, Friedhelm Bladt, Andree Blaukat, Deborah Stroka, María Rodríguez Martínez, Yitzhak Zimmer, Michaela Medová
Clinical Cancer Research.2016; 22(21): 5322. CrossRef
Potential Role of CD133 Expression in the Susceptibility of Human Liver Cancer Stem-Like Cells to TRAIL
Su-Hoon Lee, Suh-Kyung Hyun, Hak-Bong Kim, Chi-Dug Kang, Sun-Hee Kim
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2016; 24(6): 495. CrossRef
GAGE12 mediates human gastric carcinoma growth and metastasis
Eun Kyung Lee, Kyung‐A. Song, Ji‐Hye Chae, Kyoung‐Mee Kim, Seok‐Hyung Kim, Myung‐Soo Kang
International Journal of Cancer.2015; 136(10): 2284. CrossRef
Identification of Long-Range Epigenetic Silencing on Chromosome 15q25 and Its Clinical Implication in Gastric Cancer
Jee-Youn Kang, Sang-Hyun Song, Jiyeon Yun, Mi-Seong Jeon, Yongjun Cha, Si-Hyun Lee, Hwang-Phill Kim, Eun-Goo Jeong, Sae-Won Han, Nam-Yun Cho, Myeong Cherl Kook, Gyeong Hoon Kang, Tae-You Kim
The American Journal of Pathology.2015; 185(3): 666. CrossRef
Targeting HIF1α Peri-operatively Increased Post-surgery Survival in a Tongue Cancer Animal Model
Soon-Hyun Ahn, Joo Yeon Choi, Dong Wook Kim, Doh Young Lee, Eun-Hui Jeon, Woo-Jin Jeong, Jin Ho Paik
Annals of Surgical Oncology.2015; 22(9): 3041. CrossRef
Combined targeting of high‐mobility group box‐1 and interleukin‐8 to control micrometastasis potential in gastric cancer
Hye Won Chung, Sunphil Jang, Hoguen Kim, Jong‐Baeck Lim
International Journal of Cancer.2015; 137(7): 1598. CrossRef
Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System
Eun-Goo Jeong, Hyung Yoo, Byeonghwa Song, Hwang-Phill Kim, Sae-Won Han, Tae-You Kim, Dong-Il Cho
Materials.2015; 8(2): 519. CrossRef
Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition
Namgyu Lee, Jung-Hee Kwon, Young Bae Kim, Seong-Hoon Kim, Sung Jin Park, Weiguang Xu, Hoe-Yune Jung, Kyong-Tai Kim, Hee Jung Wang, Kwan Yong Choi
Oncotarget.2015; 6(30): 30130. CrossRef
Zipper-interacting protein kinase promotes epithelial-mesenchymal transition, invasion and metastasis through AKT and NF-κB signaling and is associated with metastasis and poor prognosis in gastric cancer patients
Jian Li, Zhijuan Deng, Zhu Wang, Dong Wang, Longjuan Zhang, Qiao Su, Yingrong Lai, Bin Li, Zexing Luo, Xu Chen, Yu Chen, Xiaohui Huang, Jieyi Ma, Wenjian Wang, Jiong Bi, Xinyuan Guan
Oncotarget.2015; 6(10): 8323. CrossRef
Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development
Fung-Yu Huang, Danny Ka-Ho Wong, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen
Oncotarget.2015; 6(33): 34941. CrossRef
Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis
H-P Kim, G-A Cho, S-W Han, J-Y Shin, E-G Jeong, S-H Song, W-C Lee, K-H Lee, D Bang, J-S Seo, J-Il Kim, T-Y Kim
Oncogene.2014; 33(47): 5434. CrossRef
p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines
Sung-Ung Moon, Jin Won Kim, Ji Hea Sung, Mi Hyun Kang, Se-Hyun Kim, Hyun Chang, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee
Cancer Research and Treatment.2014; 47(3): 501. CrossRef
Decreased Mitochondrial OGG1 Expression is Linked to Mitochondrial Defects and Delayed Hepatoma Cell Growth
Young-Kyoung Lee, Hwang-Guem Youn, Hee-Jung Wang, Gyesoon Yoon
Molecules and Cells.2013; 35(6): 489. CrossRef
Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor
Seon-Hyeong Lee, Nayeon Kim, Se-Jin Kim, Jaewhan Song, Young-Dae Gong, Soo-Youl Kim
Journal of Cancer Research and Clinical Oncology.2013; 139(8): 1279. CrossRef
Large-scale profiling and identification of potential regulatory mechanisms for allelic gene expression in colorectal cancer cells
Robin Dong-Woo Lee, Min-Young Song, Jong-Keuk Lee
Gene.2013; 512(1): 16. CrossRef
Claudin-1 induces epithelial–mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells
Y Suh, C-H Yoon, R-K Kim, E-J Lim, Y S Oh, S-G Hwang, S An, G Yoon, M C Gye, J-M Yi, M-J Kim, S-J Lee
Oncogene.2013; 32(41): 4873. CrossRef
p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax
CHAE WON KIM, JING NAN LU, SE-IL GO, JI HYUN JUNG, SANG MI YI, JAE-HOON JEONG, YOUNG-SOOL HAH, MYUNG SHIN HAN, JEONG WOO PARK, WON SUP LEE, YOUNG JOO MIN
International Journal of Oncology.2013; 43(5): 1495. CrossRef
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim, Yung-Jue Bang
Molecular Cancer Therapeutics.2013; 12(6): 865. CrossRef
Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
Hyun-Jin Nam, Seock-Ah Im, Do-Youn Oh, Paul Elvin, Hwang-Phill Kim, Young-Kwang Yoon, Ahrum Min, Sang-Hyun Song, Sae-Won Han, Tae-You Kim, Yung-Jue Bang
Molecular Cancer Therapeutics.2013; 12(1): 16. CrossRef
Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer
Hyun-A Kim, Bon-Kyoung Koo, Ji-Hoon Cho, Yoon-Young Kim, Jinwoo Seong, Hee Jin Chang, Young Min Oh, Daniel E. Stange, Jae-Gahb Park, Daehee Hwang, Young-Yun Kong
Journal of Clinical Investigation.2012; 122(9): 3248. CrossRef
Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells
Young-Kwang Yoon, Hwang-Phill Kim, Sang-Hyun Song, Sae-Won Han, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim
Cancer Letters.2012; 316(1): 77. CrossRef
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines
Hyun-Jin Nam, Hwang-Phill Kim, Young-Kwang Yoon, Sang-Hyun Song, Ah-Rum Min, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang
Investigational New Drugs.2012; 30(6): 2148. CrossRef
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases
Jun-Xiang Zhang, Da-Qiang Li, Aiwu Ruth He, Mona Motwani, Vasilis Vasiliou, Jeyanthy Eswaran, Lopa Mishra, Rakesh Kumar
Hepatology.2012; 55(6): 1840. CrossRef
Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer
Young-Kwang Yoon, Seock-Ah Im, Ahrum Min, Hwang-Phill Kim, Hyung-Seok Hur, Kyung-Hun Lee, Sae-Won Han, Sang-Hyun Song, Do Youn Oh, Tae-You Kim, Woo Ho Kim, Yung-Jue Bang
Cancer Letters.2012; 321(2): 128. CrossRef
Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody
Jun Gyu Kim, Min Jueng Kang, Young-Kwang Yoon, Hwang-Phill Kim, Jinah Park, Sang-Hyun Song, Sae-Won Han, Jong-Wan Park, Gyeong Hoon Kang, Keon Wook Kang, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang, Eugene C. Yi, Tae-You Kim, Frank T. Kolligs
PLoS ONE.2012; 7(3): e33322. CrossRef
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
EUNJU PARK, JINAH PARK, SAE-WON HAN, SEOCK-AH IM, TAE-YOU KIM, DO-YOUN OH, YUNG-JUE BANG
International Journal of Oncology.2012; 40(4): 1259. CrossRef
Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis
Sunyoung Chae, Young Bae Kim, Jong-Soo Lee, Hyeseong Cho
American Journal of Physiology-Gastrointestinal and Liver Physiology.2012; 302(9): G1016. CrossRef
Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
Hyun-Jin Nam, Keith A. Ching, Julie Kan, Hwang-Phill Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, James G. Christensen, Do-Youn Oh, Yung-Jue Bang
Molecular Cancer Therapeutics.2012; 11(2): 439. CrossRef
Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells
Sung-Chul Lim, Hong-Quan Duong, Jeong Eun Choi, Tae-Bum Lee, Ju-Hee Kang, Seung Hyun Oh, Song Iy Han
Carcinogenesis.2011; 32(5): 723. CrossRef
Decreased lactate dehydrogenase B expression enhances claudin 1-mediated hepatoma cell invasiveness via mitochondrial defects
June-Hyung Kim, Ei-Lyoung Kim, Young-Kyoung Lee, Chan-Bae Park, Bong-Wan Kim, Hee-Jung Wang, Chang-Hwan Yoon, Su-Jae Lee, Gyesoon Yoon
Experimental Cell Research.2011; 317(8): 1108. CrossRef
Antitumor activity of NVP‐AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins
Kyung‐Hun Lee, Ju‐Hee Lee, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, Do‐Youn Oh, Yung‐Jue Bang
Cancer Science.2011; 102(7): 1388. CrossRef
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
Hyun-Jin Nam, Hwang-Phill Kim, Young-Kwang Yoon, Hyung-Seok Hur, Sang-Hyun Song, Maeng-Sup Kim, Gwan-Sun Lee, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang
Cancer Letters.2011; 302(2): 155. CrossRef
Inhibition of Histone Deacetylase 10 Induces Thioredoxin-Interacting Protein and Causes Accumulation of Reactive Oxygen Species in SNU-620 Human Gastric Cancer Cells
Ju-Hee Lee, Eun-Goo Jeong, Moon-Chang Choi, Sung-Hak Kim, Jung-Hyun Park, Sang-Hyun Song, Jinah Park, Yung-Jue Bang, Tae-You Kim
Molecules and Cells.2010; 30(2): 107. CrossRef
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Young-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, Hyung-Seok Hur, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim
Molecular Cancer Therapeutics.2009; 8(9): 2526. CrossRef
Adaptive and Robust Methods of Reconstruction (ARMOR) for Thermoacoustic Tomography
Yao Xie, Yao Xie, Bin Guo, Bin Guo, Jian Li, Geng Ku, L.V. Wang
IEEE Transactions on Biomedical Engineering.2008; 55(12): 2741. CrossRef
Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors
Jung-Hyun Park, Sung-Hak Kim, Moon-Chang Choi, Juhee Lee, Do-Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim
Biochemical and Biophysical Research Communications.2008; 368(2): 318. CrossRef
Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers
Yeonjoo Jung, Jinah Park, Yung-Jue Bang, Tae-You Kim
Laboratory Investigation.2008; 88(2): 153. CrossRef
Enzastaurin, a Protein Kinase Cβ Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells
Keun-Wook Lee, Sang Gyun Kim, Hwang-Phill Kim, Euna Kwon, Jiran You, Hyung-Jun Choi, Jung-Hyun Park, Byeong-Cheol Kang, Seock-Ah Im, Tae-You Kim, Woo Ho Kim, Yung-Jue Bang
Cancer Research.2008; 68(6): 1916. CrossRef
Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy
Yeonjoo Jung, Jinah Park, Tai Young Kim, Jung-Hyun Park, Hyun-Soon Jong, Seock-Ah Im, Keith D. Robertson, Yung-Jue Bang, Tae-You Kim
Journal of Molecular Medicine.2007; 85(10): 1137. CrossRef
Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer
M Nojima, H Suzuki, M Toyota, Y Watanabe, R Maruyama, S Sasaki, Y Sasaki, H Mita, N Nishikawa, K Yamaguchi, K Hirata, F Itoh, T Tokino, M Mori, K Imai, Y Shinomura
Oncogene.2007; 26(32): 4699. CrossRef
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
Ju-Hee Lee, Jung-Hyun Park, Yeonjoo Jung, Jee-Hyun Kim, Hyun-Soon Jong, Tae-You Kim, Yung-Jue Bang
Molecular Cancer Therapeutics.2006; 5(12): 3085. CrossRef

33,008 View

511 Download

86 Crossref

Original Articles

Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia

Dae Kyung Sohn, Seung-Yong Jeong, Hyo Seong Choi, Seok-Byung Lim, Jin Myeong Huh, Dae-Hyun Kim, Dae Yong Kim, Young Hoon Kim, Hee Jin Chang, Kyung Hae Jung, Joong-Bae Ahn, Hyun Kyung Kim, Jae-Gahb Park

Cancer Res Treat. 2005;37(1):20-23.   Published online February 28, 2005

DOI: https://doi.org/10.4143/crt.2005.37.1.20

Abstract PDF PubReader ePub

Purpose
This study was designed to investigate the validity of a single immunochemical fecal occult blood test (FOBT) for detection of colorectal neoplasia.
Materials and Methods
A total of 3,794 average-risk screenees and 304 colorectal cancer patients admitted to the National Cancer Center, Korea, between May 2001 and November 2002, were studied prospectively. All screenees and admitted patients underwent FOBT and total colonoscopic examinations. Stools were self-collected, and examined using an immunochemical fecal occult blood test (OC-hemodia®, Eiken Chemical Co. Tokyo, Japan) and an OC-sensor analyzer® (Eiken Chemical Co. Tokyo, Japan).
Results
Of the 3,794 asymptomatic screenees, the colonoscopy identified colorectal adenomas and cancers in 613 (16.2%) and 12 (0.3%) subjects, respectively. The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The false positive rate of FOBT for colorectal cancer in screenees was 1.19%. For the total 316 colorectal cancer cases (including 12 cases from screenees), the FOBT sensitivities according to the T-stage were 38.5, 75.0%, 78.9 and 79.2% for T1, 2, 3 and 4 cancers, respectively. The sensitivities according to the Dukes stages A, B and C were 63.4, 79.3 and 78.6%, respectively.
Conclusion
The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The sensitivities of FOBT were about 80% for Dukes B or C colorectal cancers and 63.4% for Dukes A.

Citations

Citations to this article as recorded by

Findings in the distal and proximal colon in colonoscopy screening after positive FIT and related pre-procedure factors
M.� Henar Núñez Rodríguez, Pilar Díez Redondo, Fausto Riu Pons, Marta Cimavilla, Andrea Loza, Manuel Perez-Miranda
Revista Española de Enfermedades Digestivas.2022;[Epub]     CrossRef
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals
Esmée J Grobbee, Pieter HA Wisse, Eline H Schreuders, Aafke van Roon, Leonie van Dam, Ann G Zauber, Iris Lansdorp-Vogelaar, Wichor Bramer, Sarah Berhane, Jonathan J Deeks, Ewout W Steyerberg, Monique E van Leerdam, Manon CW Spaander, Ernst J Kuipers
Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
Potential Modifiers and Different Cut-offs in Diagnostic Accuracy of Fecal Immunochemical Test in Detecting Advanced Colon Neoplasia: A Diagnostic Test Accuracy Meta-analysis
Mohammad Yaghoobi, Parsa Mehraban Far, Lawrence Mbuagbaw, Yuhong Yuan, David Armstrong, Lehana Thabane, Paul Moayyedi
Middle East Journal of Digestive Diseases.2022; 14(4): 382.     CrossRef
Guidelines for accreditation of endoscopy units: quality measures from the Korean Society of Coloproctology
Rumi Shin, Seongdae Lee, Kyung-Su Han, Dae Kyung Sohn, Sang Hui Moon, Dong Hyun Choi, Bong-Hyeon Kye, Hae-Jung Son, Sun Il Lee, Sumin Si, Won-Kyung Kang
Annals of Surgical Treatment and Research.2021; 100(3): 154.     CrossRef
Screening for Colorectal Cancer
Jennifer S. Lin, Leslie A. Perdue, Nora B. Henrikson, Sarah I. Bean, Paula R. Blasi
JAMA.2021; 325(19): 1978.     CrossRef
Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy
Nao Kobayashi, Takahiro Oike, Nobuteru Kubo, Yuhei Miyasaka, Tatsuji Mizukami, Hiro Sato, Akiko Adachi, Hiroyuki Katoh, Hidemasa Kawamura, Tatsuya Ohno
Cancers.2021; 13(17): 4481.     CrossRef
Evaluation of the Cut-Off Value of Fecal Immunochemical Test for Colorectal Cancer Screening during Health Checkups
Hye-Ran Park, Eun-Hee Nah, Jong-Seon Lee, Seon Cho
Journal of Laboratory Medicine and Quality Assurance.2021; 43(4): 190.     CrossRef
Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis
Tobias Niedermaier, Yesilda Balavarca, Hermann Brenner
American Journal of Gastroenterology.2020; 115(1): 56.     CrossRef
Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location
Tobias Niedermaier, Kaja Tikk, Anton Gies, Stefanie Bieck, Hermann Brenner
Clinical Gastroenterology and Hepatology.2020; 18(13): 2920.     CrossRef
Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps
Thomas F. Imperiale, Rachel N. Gruber, Timothy E. Stump, Thomas W. Emmett, Patrick O. Monahan
Annals of Internal Medicine.2019; 170(5): 319.     CrossRef
Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis
Kevin Selby, Emma H. Levine, Cecilia Doan, Anton Gies, Hermann Brenner, Charles Quesenberry, Jeffrey K. Lee, Douglas A. Corley
Gastroenterology.2019; 157(6): 1494.     CrossRef
Quantitative fecal immunochemical tests for colorectal cancer screening
Anton Gies, Megha Bhardwaj, Christian Stock, Petra Schrotz‐King, Hermann Brenner
International Journal of Cancer.2018; 143(2): 234.     CrossRef
Prevalence of functional gastrointestinal disorders in adults with systemic lupus erythematosus
M García-Carrasco, C Mendoza-Pinto, M A Autrán-Limón, E Herrera Robles, S Méndez Martínez, I Etchegaray Morales, Á Montiel Jarquín, J L Gálvez Romero, P Soto-Santillán, J Galindo-Herrera, A López-Colombo
Lupus.2018; 27(5): 788.     CrossRef
Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea
Dae Ho Kim, Jae Myung Cha, Min Seob Kwak, Jin Young Yoon, Young-Hak Cho, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
Gut and Liver.2018; 12(2): 183.     CrossRef
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
Gastroenterology.2017; 152(5): 1217.     CrossRef
Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
Gastrointestinal Endoscopy.2017; 85(1): 2.     CrossRef
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
Douglas J Robertson, Jeffrey K Lee, Richard C Boland, Jason A Dominitz, Francis M Giardiello, David A Johnson, Tonya Kaltenbach, David Lieberman, Theodore R Levin, Douglas K Rex
American Journal of Gastroenterology.2017; 112(1): 37.     CrossRef
Risk Factors for False Fecal Immunochemical Test Results in Colorectal Cancer Screening
Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
Journal of Clinical Gastroenterology.2017; 51(2): 151.     CrossRef
Which Fecal Immunochemical Test Should I Choose?
Jeanette M. Daly, Yinghui Xu, Barcey T. Levy
Journal of Primary Care & Community Health.2017; 8(4): 264.     CrossRef
Cancer-Type Oatp1B3 mRNA Has the Potential to Become a Detection and Prognostic Biomarker for Human Colorectal Cancer
Yuchen Sun, Manami Harada, Osamu Shimozato, Hiroaki Souda, Nobuhiro Takiguchi, Yoshihiro Nabeya, Takehiko Kamijo, Hidetaka Akita, Naohiko Anzai, Kan Chiba, Tomomi Furihata
Biomarkers in Medicine.2017; 11(8): 629.     CrossRef
Screening of colorectal cancer: present and future
Marcello Maida, Fabio Salvatore Macaluso, Gianluca Ianiro, Francesca Mangiola, Emanuele Sinagra, Georgina Hold, Carlo Maida, Giovanni Cammarota, Antonio Gasbarrini, Giuseppe Scarpulla
Expert Review of Anticancer Therapy.2017; 17(12): 1131.     CrossRef
Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance
Min Seob Kwak, Jae Myung Cha, Jin Young Yoon, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
Journal of Clinical Gastroenterology.2017; 51(9): 825.     CrossRef
Use of a Low Cut-Off Value for the Fecal Immunochemical Test Enables Better Detection of Proximal Neoplasia
Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jung Won Jeun, Jun Uk Lim
Digestive Diseases and Sciences.2013; 58(11): 3256.     CrossRef
Performance of the Fecal Immunochemical Test Is Not Decreased by High Ambient Temperature in the Rapid Return System
Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park, Jung Won Jeun, Jun Uk Lim, Sang-Hyun Hwang
Digestive Diseases and Sciences.2012; 57(8): 2178.     CrossRef
A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program
Mi Jin Park, Kui Son Choi, You Kyoung Lee, Jae Kwan Jun, Hoo-Yeon Lee
Scandinavian Journal of Gastroenterology.2012; 47(4): 461.     CrossRef
Clinical Features of Colorectal Cancer Detected by the National Cancer Screening Program
Dae-Do Park, Rumi Shin, Ji-Sun Kim, Heung-Kwon Oh, Seung-Yong Jeong, Kyu Joo Park, Jae-Gahb Park
Journal of the Korean Society of Coloproctology.2010; 26(6): 420.     CrossRef
The Significance of Fecal Immunochemical Test to Screen for Colorectal Cancer in National Cancer Screening Program
Jun Uk Lim, Na Young Bae, Won Koung Song, Jae Myung Cha, Joung Il Lee
Intestinal Research.2010; 8(2): 126.     CrossRef
False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening
Leo G.M. van Rossum, Anne F. van Rijn, Martijn G.H. van Oijen, Paul Fockens, Robert J.F. Laheij, Andre L.M. Verbeek, Jan B.M.J. Jansen, Evelien Dekker
International Journal of Cancer.2009; 125(4): 746.     CrossRef
Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme
L G M van Rossum, A F van Rijn, R J F Laheij, M G H van Oijen, P Fockens, J B M J Jansen, A L M Verbeek, E Dekker
British Journal of Cancer.2009; 101(8): 1274.     CrossRef
Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population
Leo G. van Rossum, Anne F. van Rijn, Robert J. Laheij, Martijn G. van Oijen, Paul Fockens, Han H. van Krieken, Andre L. Verbeek, Jan B. Jansen, Evelien Dekker
Gastroenterology.2008; 135(1): 82.     CrossRef

10,944 View

89 Download

30 Crossref

High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Followed by Autologous Stem-Cell Transplantation for Metastatic Breast Cancer Patients: A 6-Year Follow-Up Result

Hee-Jung Sohn, Sang-Hee Kim, Gyeong-Won Lee, Shin Kim, Hye Jin Kang, Jin-Hee Ahn, Sung-Bae Kim, Sang-We Kim, Woo Kun Kim, Cheolwon Suh

Cancer Res Treat. 2005;37(1):24-30.   Published online February 28, 2005

DOI: https://doi.org/10.4143/crt.2005.37.1.24

Abstract PDF PubReader ePub

Purpose
The benefit of high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) is controversial. We evaluated the efficacy and safety of HDC with cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) for MBC patients.
Materials and Methods
From September 1994 to December 1999, 23 MBC patients were enrolled. All the patients received 2 to 10 cycles of induction chemotherapy. Before transplantation, 12 patients were in complete response (CR), nine were in partial response (PR), and two had progressive disease (PD). The HDC regimen consisted of cyclophosphamide 1,500 mg/m²/day, thiotepa 125 mg/m²/day and carboplatin 200 mg/m²/day intravenously for 4 consecutive days.
Results
After ASCT, 13 patients (56%) had a CR, five (22%) had a PR, three (13%) had no change, while two (9%) showed a PD. Seventeen patients relapsed or progressed during the median follow-up of 78 months. The median progression-free survival (PFS) time was 11 months and the median overall survival (OS) time was 23 months. The 5-year PFS and OS rates were 22% and 25%, respectively. On the multivariate analyses, less than 4 involved lymph nodes was predictive of a better PFS and OS.
Conclusion
HDC with CTCb for MBC has acceptable toxicity; however, this treatment does not show a survival benefit.

Citations

Citations to this article as recorded by

Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Jung Sun Park, Cheolwon Suh
The Korean Journal of Medicine.2021; 96(6): 501.     CrossRef

8,978 View

48 Download

1 Crossref

Treatment Outcome of Limited Stage Hodgkin's Disease

Jung Hun Kang, Yong Chan Ahn, Won Seog Kim, Won Ki Kang

Cancer Res Treat. 2005;37(1):31-36.   Published online February 28, 2005

DOI: https://doi.org/10.4143/crt.2005.37.1.31

Abstract PDF PubReader ePub

Purpose
The 10-year overall survival rate following conventional treatments for patients with limited-stage Hodgkin's disease (HD) exceeds 90%. However, the clinical features and treatment outcome of HD in Korea have not been extensively characterized due to its low incidence. In this study, we attempted to analyze the treatment outcome of different modalities in limited stage HD patients.
Materials and Methods
Twenty one Hodgkin's disease patients, referred to the Samsung Medical Center between January 1997 and December 2003, were enrolled in this study. Limited stage Hodgkin's disease was subdivided into low and high risk groups. All evaluable patients received treatment.
Results
There were 13 and 8 patients in the low and high risk groups, respectively. Eighteen patients (86%) obtained complete response (CR) and 3 patients (14%) achieved an undetermined complete response (CRu). Fourteen (67%), 4 (19%) and 3 (14%) cases received combination chemotherapy, radiotherapy alone and chemotherapy alone, respectively. Four cases relapsed and 2 obtained a second CR. The 5-year overall and disease-free survival rates were 90 and 72%, respectively, for all patients. The median follow-up duration was 31 months. There was no difference in disease free survival (DFS) between the low and high risk groups. Although 12 cases had neutropenia greater than grade III, none experienced neutropenic fever.
Conclusion
The treatment outcome of limited-stage HD was excellent, regardless to the initial treatment modality.

7,719 View

42 Download

A Preliminary Results of a Randomized Trial Comparing Monthly 5-flourouracil and Cisplatin to Weekly Cisplatin Alone Combined with Concurrent Radiotherapy for Locally Advanced Cervical Cancer

Young Seok Kim, Seong Soo Shin, Eun Kyung Choi, Jong Hoon Kim, Seung Do Ahn, Sang-wook Lee, Heon-Jin Park, Young-Tak Kim, Jung-Eun Mok, Joo-Hyun Nam

Cancer Res Treat. 2005;37(1):37-43.   Published online February 28, 2005

DOI: https://doi.org/10.4143/crt.2005.37.1.37

Abstract PDF PubReader ePub

Purpose
To determine the superior chemotherapeutic regimen between monthly 5-FU plus cisplatin (FP) and weekly cisplatin alone in concurrent chemoradiotherapy for locally advanced cervical cancer, the compliance of treatment, response, survival and toxicities were analyzed between the two arms.
Materials and Methods
Between March 1998 and December 2001, 61 patients with locally advanced cervical cancer (stage IIB through IVA) and negative para-aortic lymph nodes were randomly assigned to either 'monthly FP' (arm I, n=34) or 'weekly cisplatin' (arm II, n=27) with concurrent radiotherapy. The patients of arm I received FP (5-FU 1,000 mg/m²/day + cisplatin 20 mg/m²/day, for 5 days, for 3 cycles at 4 week intervals) and those of arm II received cisplatin (30 mg/m²/day, for 6 cycles at 1 week intervals) with concurrent radiotherapy. The radiotherapy consisted of 41.4~50.4 Gy external beam irradiation in 23~28 fractions to the whole pelvis, with high dose rate brachytherapy delivering a dose of 30~35 Gy in 6~7 fractions to point A. During the brachytherapy, a parametrial boost was delivered. The median follow-up period for survivors was 44 months.
Results
The compliance of treatment in monthly FP weekly cisplatin arms were 62 and 81%, respectively. The complete response rates at 3 months were 96 and 88% in arms I and II, respectively. The 4-year overall survival and disease free survival rates were 64 and 54% in the arm I and 77 and 66% in the arm II, respectively. The incidence of hematologic toxicity more than grade 2 was 29% in the arm I and 15% in the arm II. Only one patient in arm I experienced grade 3 gastrointestinal toxicity. No severe genitourinary toxicity was observed.
Conclusion
No significant difference was observed in the compliance, responses, survival rates and acute toxicities between the two treatment arms. More patients and further follow up will be required.

Citations

Citations to this article as recorded by

American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer
Jyoti Mayadev, Akila Viswanathan, Yu Liu, Chin-Shang Li, Kevin Albuquerque, Antonio L. Damato, Sushil Beriwal, Beth Erickson
Brachytherapy.2017; 16(1): 22.     CrossRef
Concurrent Weekly Cisplatin Versus Triweekly Cisplatin with Radiotherapy in the Treatment of Cervical Cancer: A Meta-analysis Result
Yan Hu, Zhi-Qiang Cai, Xiao-Yan Su
Asian Pacific Journal of Cancer Prevention.2012; 13(9): 4301.     CrossRef
Laparoscopy-Assisted Intracavitary Radiotherapy Tandem Placement for Patients With Cervical Cancer
Myong Cheol Lim, Dae Chul Jung, Joo-Young Kim, Sang-Yoon Park
International Journal of Gynecologic Cancer.2009; 19(6): 1125.     CrossRef
Adoptive Transfer of Human Papillomavirus E7-specific CTL Enhances Tumor Chemoresponse Through the Perforin/Granzyme-mediated Pathway
Jeong-Im Sin, Jung-Min Kim, Sung Hwa Bae, In Hee Lee, Jong Sup Park, Hun Mo Ryoo
Molecular Therapy.2009; 17(5): 906.     CrossRef

9,695 View

56 Download

4 Crossref

Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized Study

Chang Wook Jeong, Hwang Gyun Jeon, Cheol Kwak, Hyeon Jeong, Sang Eun Lee

Cancer Res Treat. 2005;37(1):44-47.   Published online February 28, 2005

DOI: https://doi.org/10.4143/crt.2005.37.1.44

Abstract PDF PubReader ePub

Purpose
A prospective study was performed to compare the efficacy and safety of intravesical mitomycin C (MMC) instillation for the prophylaxis of bladder cancer at different concentrations (30 mg or 40 mg).
Materials and Methods
Ninety-seven patients that received complete transurethral resection for superficial bladder cancer were divided into two-randomized groups. One group (n=53) received 30 mg and the other group (n=44) received 40 mg dose of MMC weekly for 8 weeks, which was followed monthly for 10 months as maintenance therapy. The recurrence rates and side effects in both groups were recorded. The mean follow-up period was 32.4 months in the 30 mg group, and 32.0 months in the 40 mg group.
Results
The overall one and two year recurrence rates were 19% and 24% in the 30 mg group, and 12% and 22% in the 40 mg group, which was not significantly different (p>0.05). Most of the side effects were mild and transient. Moreover, the rates of the individual side effects were not statistically different in the two groups.
Conclusion
Our comparison of 30 mg and 40 mg intravesical MMC instillation showed no difference in either response or side effects. Thus, we tentatively conclude that we can use 30 mg instead of 40 mg as an intravesical MMC instillation dose.

Citations

Citations to this article as recorded by

Mathematical model of MMC chemotherapy for non-invasive bladder cancer treatment
Marom Yosef, Svetlana Bunimovich-Mendrazitsky
Frontiers in Oncology.2024;[Epub]     CrossRef
The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
Pietro Scilipoti, Aleksander Ślusarczyk, Mario de Angelis, Francesco Soria, Benjamin Pradere, Wojciech Krajewski, David D’Andrea, Andrea Mari, Francesco Del Giudice, Renate Pichler, José Daniel Subiela, Luca Afferi, Simone Albisinni, Laura Mertens, Ekater
European Urology Oncology.2024;[Epub]     CrossRef
Gestion pratique de l’ECBU au cours des instillations endovésicales de Bacille de Calmette et Guérin (BCG) et de Mitomycine C (MMC)
F. Saint
Progrès en Urologie - FMC.2021; 31(4): F121.     CrossRef
Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer
Yu-Ching Wen, Liang-Ming Lee, Yung-Wei Lin, Syuan-Hao Syu, Ke-Hsun Lin, Yen-Chun Fan, Hsin-Lun Lee, Benjamin Chung Howe Lai, Hung-Jen Shih
International Journal of Hyperthermia.2021; 38(1): 1627.     CrossRef
Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder
Sunita Saxena, Usha Agrawal, Abhilasha Agarwal, Nandagudi Srinivasa Murthy, Nayan Kumar Mohanty
BJU International.2006; 98(5): 1012.     CrossRef

7,867 View

58 Download

5 Crossref

Clinical Prognostic Factors for Radical Cystectomy in Bladder Cancer

Seung Hyun Jeon, Sung-Hyun Jeon, Sung-Goo Chang

Cancer Res Treat. 2005;37(1):48-53.   Published online February 28, 2005

DOI: https://doi.org/10.4143/crt.2005.37.1.48

Abstract PDF PubReader ePub

Purpose
We investigated the effects of radical cystectomy and the prognostic factors that affect the survival of bladder cancer patients.
Materials and Methods
From 1979 to 2002, 59 patients with long-term follow up results of at least 2 years were enrolled in this study. Indications for surgery included muscle invasive bladder cancer and high-risk superficial bladder cancer. The cancer specific and recurrence free survival rates with respect to the possible prognostic factors were determined using Kaplan-Meier statistics.
Results
The mean patient age was 62.8 years (M: 48, F: 11), and the estimated 5- and 10-year survival rates were 62% and 39.4%, respectively. The median time to local or systemic recurrence was 16 months (range: 5~100), and the average survival durations after local and systemic recurrence were 14.4 months and 12.7 months, respectively. Pathologic stage, tumor grade, mean nuclear area, sex and lymphatic invasion were significant factors by univariate analysis (p<0.05). The disease related survival rate in patients having progression from an initial superficial tumor was lower than for those patients who displayed muscle invasive disease at the initial treatment. Multivariate analysis identified pathologic stage and lymphatic invasion as independent prognostic factors.
Conclusions
Radical cystectomy for organ-confined cancer showed favorable 5- and 10-year survival rates. The survival rate for patients with progression from an initial superficial tumor was worse than for those patients with invasive tumor at the initial presentation. The most significant independent prognostic factors were the pathologic stage and the presence of lymphatic invasion, which were highly correlated with all the investigated disease endpoints.

Citations

Citations to this article as recorded by

Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer
Hriday P. Bhambhvani, Alvaro Zamora, Eugene Shkolyar, Kris Prado, Daniel R. Greenberg, Alex M. Kasman, Joseph Liao, Sumit Shah, Sandy Srinivas, Eila C. Skinner, Jay B. Shah
Urologic Oncology: Seminars and Original Investigations.2021; 39(3): 193.e7.     CrossRef
Alterations of Global Histone H3K9 and H3K27 Methylation Levels in Bladder Cancer
Jörg Ellinger, Anne Bachmann, Friederike Göke, Turang E. Behbahani, Claudia Baumann, Lukas C. Heukamp, Sebastian Rogenhofer, Stefan C. Müller
Urologia Internationalis.2014; 93(1): 113.     CrossRef
Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer
Ann-Christin Schneider, Lukas C. Heukamp, Sebastian Rogenhofer, Guido Fechner, Patrick J. Bastian, Alexander von Ruecker, Stefan C. Müller, Jörg Ellinger
BJU International.2011; 108(8b): E290.     CrossRef

9,105 View

71 Download

3 Crossref

cDNA Microarray Analysis of Differential Gene Expression in Gastric Cancer Cells Sensitive and Resistant to 5-Fluorouracil and Cisplatin

Myung-Ju Ahn, Young-Do Yoo, Ki-Hwan Lee, Joon-Ik Ahn, Dong-Hyun Yu, Hye-Sook Lee, Ho-Suck Oh, Jung-Hye Choi, Yong-Sung Lee

Cancer Res Treat. 2005;37(1):54-62.   Published online February 28, 2005

DOI: https://doi.org/10.4143/crt.2005.37.1.54

Abstract PDF PubReader ePub

Purpose
Gastric cancer is one of the most prevalent cancers worldwide. 5-fluorouracil (5-FU) and cisplatin are the most commonly used drugs for the treatment of gastric cancer. However, a significant number of tumors often fail to respond to chemotherapy.
Materials and Methods
To better understand the molecular mechanisms underlying drug resistance in gastric cancer the gene expression in gastric cancer cells, which were either sensitive or resistant to 5-FU and cisplatin, were examined using cDNA microarray analysis. To confirm the differential gene expression, as determined using the microarray, semiquantitative RT-PCR was performed on a subset of differentially expressed cDNAs.
Results
69 and 45 genes, which were either up-regulated (9 and 22 genes) or down-regulated (60 and 25 genes), were identified in 5-FU- and cisplatin-resistant cells, respectively. Several genes, such as adaptor-related protein complex 1 and baculoviral IAP repeat-containing 3, were up-regulated in both drug-resistant cell types. Several genes, such as the ras homolog gene family, tropomyosin, tumor rejection antigen, protein disulfide isomerase-related protein, melanocortin 1 receptor, defensin, cyclophilin B, dual specificity phosphatase 8 and hepatocyte nuclear factor 3, were down-regulated in both drugresistant cell types.
Conclusion
These findings show that cDNA microarray analysis can be used to obtain gene expression profiles that reflect the effect of anticancer drugs on gastric cancer cells. Such data may lead to the assigning of signature expression profiles of drug-resistant tumors, which may help predict responses to drugs and assist in the design of tailored therapeutic regimens to overcome drug resistance.

Citations

Citations to this article as recorded by

Molecular classification and prediction in gastric cancer
Xiandong Lin, Yongzhong Zhao, Won-min Song, Bin Zhang
Computational and Structural Biotechnology Journal.2015; 13: 448.     CrossRef
Identification of Differentially-Expressed Genes in Intestinal Gastric Cancer by Microarray Analysis
Shizhu Zang, Ruifang Guo, Rui Xing, Liang Zhang, Wenmei Li, Min Zhao, Jingyuan Fang, Fulian Hu, Bin Kang, Yonghong Ren, Yonglong Zhuang, Siqi Liu, Rong Wang, Xianghong Li, Yingyan Yu, Jing Cheng, Youyong Lu
Genomics, Proteomics & Bioinformatics.2014; 12(6): 276.     CrossRef
Protein disulfide isomerase in redox cell signaling and homeostasis
Francisco R.M. Laurindo, Luciana A. Pescatore, Denise de Castro Fernandes
Free Radical Biology and Medicine.2012; 52(9): 1954.     CrossRef

10,098 View

61 Download

3 Crossref

Immunization with Adenoviral Vectors Carrying Recombinant IL-12 and E7 Enhanced the Antitumor Immunity against Human Papillomavirus 16-associated Tumor

Eun-Kyung Park, Young-Wook Kim, Joon-Mo Lee, Sung-Eun NamKoong, Do-Gang Kim, Heung-Jae Chun, Byoung-Don Han, Su-Mi Bae, Hyun-Sun Jin, Jeong-Im Sin, Woong-Shick Ahn

Cancer Res Treat. 2005;37(1):63-70.   Published online February 28, 2005

DOI: https://doi.org/10.4143/crt.2005.37.1.63

Abstract PDF PubReader ePub

Purpose
Human papillomavirus (HPV) infection has a significant role in cervical carcinogenesis, and HPV oncoprotein E7 plays an important part in the formation and maintenance of cervical cancer. Interleukin-12 (IL-12) has been reported to induce a cellular immune response, and to suppress the tumor growth and the E7 production. Here we describe the use of adenoviral delivery of the HPV 16 E7 subunit (AdE7) along with adenoviral delivery of IL-12 (AdIL-12) in mice with HPV-associated tumors.
Materials and Methods
Mice were injected with TC-1 cells to establish TC-1 tumor, and then they were immunized with AdIL-12 and/or AdE7 intratumorally. The anti tumor effects induced by AdIL-12 and/or E7 were evaluated by measuring the size of the tumor. E7-specific antibody and INF-γ production in sera, and the T-helper cell proliferative responses were then measured. Cytotoxic T-lymphocyte (CTL) and T cell subset depletion studies were also performed.
Results
Combined AdIL-12 and AdE7 infection at the tumor sites significantly enhanced the antitumor effects more than that of AdIL-12 or AdE7 single infection. This combined infection resulted in regression of the 9 mm sized tumors in 80% of animals as compare to the PBS group. E7-specific antibody and INF-γ production in the sera, and the T-helper cell proliferative responses were significantly higher with coinfection of AdIL-12 and AdE7 than with AdIL-12 or AdE7 alone. CTL response induced by AdIL-12 and AdE7 in the coinjected group suggested that tumor suppression was mediated by mostly CD8+ and only a little by the CD4+ T cells.
Conclusion
IL-12 and E7 application using adenovirus vector showed antitumor immunity effects against TC-1 tumor, and this system could be use in clinical applications for HPV-associated cancer. (ED note: nice abstract.)

Citations

Citations to this article as recorded by

Development of a replication‐deficient adenoviral vector‐based vaccine candidate for the interception of HPV16‐ and HPV18‐induced infections and disease
Selina Khan, Koen Oosterhuis, Kerstin Wunderlich, Evelien M. Bunnik, Melissa Bhaggoe, Satish Boedhoe, Santusha Karia, Renske D.M. Steenbergen, Leontien Bosch, Jan Serroyen, Sarah Janssen, Hanneke Schuitemaker, Jort Vellinga, Gert Scheper, Roland Zahn, Jer
International Journal of Cancer.2017; 141(2): 393.     CrossRef
Immune responses and protective efficacy of a recombinant swinepox virus expressing HA1 against swine H1N1 influenza virus in mice and pigs
Jiarong Xu, Dongyan Huang, shichao Liu, Huixing Lin, Haodan Zhu, Bao Liu, Chengping Lu
Vaccine.2012; 30(20): 3119.     CrossRef
Immune responses and protection efficacy of a recombinant swinepox virus expressing HA1 against swine H3N2 influenza virus in mice and pigs
Jiarong Xu, Dongyan Huang, Shichao Liu, Huixing Lin, Haodan Zhu, Bao Liu, Chengping Lu
Virus Research.2012; 167(2): 188.     CrossRef

8,622 View

37 Download

3 Crossref

Identification of CLP36 as a Tumor Antigen that Induces an Antibody Response in Pancreatic Cancer

Su-Hyung Hong

Cancer Res Treat. 2005;37(1):71-77.   Published online February 28, 2005

DOI: https://doi.org/10.4143/crt.2005.37.1.71

Abstract PDF PubReader ePub

Purpose
Pancreatic cancer has a poor prognosis, due in part to the lack of an effective approach for its early detection. The identification of tumor antigens potentially provides a means for the early diagnosis. The purpose of this study was to use a proteomic approach for the identification of proteins that commonly induce a humoral response in patients with pancreatic cancer.
Materials and Methods
Proteins from the pancreatic adenocarcinoma cell line, BxPC3, were subjected to two-dimensional polyacrylamide gel electrophoresis, followed by Western blot analysis, where individual sera were tested for autoantibodies. Sera from 36 patients with pancreatic adenocarcinoma, and 68 from control groups (14 from lung adenocarcinoma, 19 from colon adenocarcinoma and 35 from healthy subjects) were analyzed. CLP36 expression was evaluated by immunohistochemical analysis and real-time PCR. The cellular localization of CLP36 as an autoantigen was investigated by Western blot analysis.
Results
The autoantibody was detected against a protein, identified by mass spectrometry as CLP36, in 14 of the 36 sera (38.9%) from patients with a pancreatic adenocarcinoma, and 3 of the 68 controls (4.4%). Immunohistochemical analysis of CLP36 in a tissue array demonstrated diffuse and consistent immunoreactivity in the pancreatic adenocarcinomas. The levels of CLP36 mRNA were highest in the pancreatic cancer cell lines of the different cells analyzed. The molecular weight of the protein displayed in the membrane-rich fraction was larger than that in the cytosolic fraction, which is likely attributable to a post-translational modification.
Conclusion
CLP36 was identified as a tumor autoantigen inducing a humoral immune response in pancreatic adenocarcinomas. More detailed studies need to be undertaken to understand whether the humoral response by CLP36 is tumor-specific.

Citations

Citations to this article as recorded by

PDZ and LIM Domain-Encoding Genes: Their Role in Cancer Development
Xinyuan Jiang, Zhiyong Xu, Sujing Jiang, Huan Wang, Mingshu Xiao, Yueli Shi, Kai Wang
Cancers.2023; 15(20): 5042.     CrossRef
miR-187/PDLIM1 Gets Involved in Gastric Cancer Progression and Cisplatin Sensitivity of Cisplatin by Mediating the Hippo-YAP Signaling Pathway
Yeru Tan, Yuehua Li, Hongbo Zhu, Xiaoping Wu, Kai Mei, Pian Li, Qiao Yang, Zhongjie Shi
Journal of Oncology.2022; 2022: 1.     CrossRef
Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer
Cuipeng Qiu, Yaru Duan, Bofei Wang, Jianxiang Shi, Peng Wang, Hua Ye, Liping Dai, Jianying Zhang, Xiao Wang
Frontiers in Immunology.2021;[Epub]     CrossRef
Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients
Prachi Gupta, Shankar Suman, Manisha Mishra, Sanjay Mishra, Nidhi Srivastava, Vijay Kumar, Pradhyumna Kumar Singh, Yogeshwer Shukla
PROTEOMICS - Clinical Applications.2016; 10(5): 564.     CrossRef
Identification of Novel Gene Targets and Functions of p21-Activated Kinase 1 during DNA Damage by Gene Expression Profiling
Mona Motwani, Da-Qiang Li, Anelia Horvath, Rakesh Kumar, Wei-Guo Zhu
PLoS ONE.2013; 8(8): e66585.     CrossRef
Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer
A. Heller, I. Zörnig, T. Müller, K. Giorgadze, C. Frei, T. Giese, F. Bergmann, J. Schmidt, J. Werner, M. W. Buchler, D. Jaeger, N. A. Giese
Cancer Immunology, Immunotherapy.2010; 59(9): 1389.     CrossRef

8,652 View

50 Download

6 Crossref

First

Prev

Page of 1

Next

Last

Previous issues